Sarcoma
A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
Subtype terms (23)
More specific conditions that are subtypes of Sarcoma in the MeSH hierarchy.
- Adenosarcoma
3 drugs approved
- Carcinosarcoma
25 drugs (17 approved, 8 experimental)
- Chondrosarcoma
59 drugs (37 approved, 22 experimental)
- Desmoplastic Small Round Cell Tumor
41 drugs (29 approved, 12 experimental)
- Endometrial Stromal Tumors
1 drug approved
- Fibrosarcoma
39 drugs (27 approved, 12 experimental)
- Hemangiosarcoma
43 drugs (27 approved, 16 experimental)
- Histiocytoma, Malignant Fibrous
3 drugs (2 approved, 1 experimental)
- Leiomyosarcoma
92 drugs (54 approved, 38 experimental)
- Liposarcoma
99 drugs (55 approved, 44 experimental)
- Lymphangiosarcoma
3 drugs (2 approved, 1 experimental)
- Mixed Tumor, Mesodermal
2 drugs approved
- Myosarcoma
2 drugs approved
- Myxosarcoma
6 drugs (3 approved, 3 experimental)
- Osteosarcoma
223 drugs (112 approved, 111 experimental)
- Phyllodes Tumor
- Sarcoma, Alveolar Soft Part
22 drugs (15 approved, 7 experimental)
- Sarcoma, Clear Cell
40 drugs (24 approved, 16 experimental)
- Sarcoma, Experimental
- Sarcoma, Kaposi
81 drugs (55 approved, 26 experimental)
- Sarcoma, Myeloid
40 drugs (32 approved, 8 experimental)
- Sarcoma, Small Cell
- Sarcoma, Synovial
75 drugs (33 approved, 42 experimental)
Drugs by status
Approved for this indication (5)
Phase 4 trials (7)
Phase 3 trials (66)
- futibatinib
- mesna
- ceritinib
- melphalan
- evofosfamide
- modafinil
- temozolomide
- trabectedin
- autologous hematopoietic stem cells
- ny-eso-1 peptides
- cyclophosphamide
- olaparib
- carboplatin
- ombrabulin
- naltrexone
- sodium thiosulfate
- vinblastine
- daunorubicin
- capmatinib
- imatinib
- regorafenib
- methotrexate
- eribulin
- cisplatin
- idarubicin
- pembrolizumab
- prednisolone
- carotuximab
- gemcitabine
- bevacizumab
- +36 more
Phase 2 trials (305)
- sirolimus
- ivosidenib
- vemurafenib
- cytokine induced killer cells
- pertuzumab
- kva12123
- fluoromisonidazole
- apx005m
- pexastimogene devacirepvec
- ql1706
- axitinib
- phenylacetic acid
- azacitidine
- enmd 2076
- Camsirubicin
- vatalanib
- ly2880070
- palifermin
- ivocizumab
- cemiplimab
- cixutumumab
- mitomycin
- sintilimab
- trastuzumab
- Anti-thymocyte Globulin (Rabbit)
- lag525
- becatecarin
- ilb2109
- lurbinectedin
- tiragolumab
- +275 more
Phase 1 trials (182)
- okn4395
- pba-0111
- mixed bacterial vaccine
- gz17-6.02
- vimseltinib
- mage-12 peptide vaccine
- idc-g305
- plerixafor
- dit309
- ef5
- ds-2243
- silicon phthalocyanine
- almond
- pnt6555
- anti-ny eso-1 tcr-transduced t cells
- gd2-sada
- pimozide
- hsv-1716
- itacitinib
- pbi-shrna ews/fli1 type 1 lpx
- dnx-2440
- btx-a51
- seneca valley virus
- autologous tumor cell vaccine
- bbi-355
- bupivacaine
- sn-38
- [ac 225]rtx-2358
- perflutren protein-type a microspheres
- ixazomib
- +152 more
Organizations
Organization Involved with Phase 4 Indications (18)
- Abbott
- Gilead Sciences
- Cipla
- GWT-TUD GmbH
- National Research Foundation, Singapore
- National Institutes of Health (NIH)
- Medical Research Council
- AIDS Malignancy Consortium
- Harvard University
- Duke University
- University of Kansas
- University of Rostock
- University of California, San Francisco
- University of Toulouse
- Henan Medical University
- University of Kwa-Zulu Natal
- AIDS Care Research in Africa
- Dermatological Society of South Africa
Organization Involved with Phase 3 Indications (107)
- NeXstar Pharmaceuticals
- Eisai
- Advenchen Laboratories, LLC
- Pfizer
- Sanofi
- Novartis
- Ariad Pharmaceuticals
- Chugai
- Gradalis, Inc.
- Immune Design
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Philogen S.p.A.
- Sequus Pharmaceuticals
- Threshold Pharmaceuticals
- Cytran
- CytRx
- Epizyme, Inc.
- PharmaMar
- Ziopharm
- AIDS Clinical Trials Group
- The Christie NHS Foundation Trust
- National Cancer Institute (NCI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Commissariat A L'energie Atomique
- University of Pennsylvania
- Albany Medical College
- Canadian Cancer Trials Group
- Children's Cancer and Leukaemia Group
- University of London
- Cooperative Weichteilsarkom Study Group
- +77 more
Organization Involved with Phase 2 Indications (274)
- Incyte
- Adaptimmune
- Ligand Pharmaceuticals
- Spectrum Pharmaceuticals
- Daiichi Sankyo
- Celgene
- Medarex
- Bristol-Myers Squibb
- Lederle
- Amgen
- Enzon
- Roche
- Astellas
- Imclone
- Morphotek
- Schering-Plough
- AstraZeneca
- Merck Serono
- Pharmacyclics
- Exelixis
- Genentech
- MedImmune
- Merck KGaA
- Plexxikon
- Agouron
- Genzyme
- AEterna Zentaris
- Sugen
- Wyeth
- AIO-Studien-gGmbH
- +244 more
Organization Involved with Phase 1 Indications (68)
- AbbVie
- Daiichi
- Seattle Genetics
- Takeda
- Aventis
- Siemens
- Arno Therapeutics
- Blaze Bioscience Inc.
- Corcept Therapeutics
- Corvus Pharmaceuticals, Inc.
- DEKK-TEC, Inc.
- Incuron
- Infinity Pharmaceuticals, Inc.
- Karyopharm Therapeutics Inc
- Light Sciences Oncology
- MacroGenics
- Merrimack Pharmaceuticals
- OncoTherapy Science, Inc.
- Presage Biosciences
- SYZ Cell Therapy Co..
- Sinobioway Cell Therapy Co., Ltd.
- Trillium Therapeutics Inc.
- Trin Therapeutics GmbH
- Strike Bio, Inc.
- German Research Foundation
- Central European Society for Anticancer Drug Research (CESAR)
- National Human Genome Research Institute (NHGRI)
- Aarhus University
- American Society of Clinical Oncology
- Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
- +38 more
Organization Involved with Other Experimental Indications (8)